Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro

Jian-Zheng Jie, Jian-Wei Wang, Jian-Guo Qu, Wei Wang, Tao Hung

INTRODUCTION
Hepatocyte growth factor (HGF), a glycoprotein consisting of 728 amino acids with a 69 kDa α-chain and a 34 kDa β-chain, affects tumor metastasis\(^1\,^2\). HGF binds to c-Met, the only HGF receptor, and causes a cascade of enzyme catalyzed reactions, triggers signal transduction and the corresponding biological effects\(^3\). In the normal condition, the paracrine influence of HGF between the epithelial and interstitial cells is strictly controlled. However, when abnormal HGF/c-Met signaling occurs, such as there is a mutation of the c-Met gene, overexpression of HGF and/or c-Met, or there is co-expression of HGF and c-Met within the same cells, c-Met may be persistently over-expressed and thereby exhibit a high-level of self-phosphorylation. All these biological activities, in turn, facilitate the occurrence, growth, infiltration, metastasis, and angiogenesis of many kinds of tumors\(^4\,^5\). The HGF/c-Met signaling pathway has been thought to play an important role in the production of many kinds of human tumors\(^6\,^7\). Studies discovering the ways to block this pathway will provide new targets for the anti-metastasis tumor treatment.

NK4, a specific antagonist of HGF discovered by Date et al\(^8\) in 1997, is a fragment from the HGF molecule that has been cut by elastase between the 478\(^{th}\) and the 479\(^{th}\) amino acid. NK4 derives its name from its structure: It is composed of the NH2-terminal hairpin domain and four subsequent kringle domains of the α-chain of HGF. NK4 contains 447 amino acids, and the molecular weight is about 50 kDa. Although NK4 competes with HGF for c-Met receptor binding, it cannot activate the c-Met receptor and induce its phosphorylation. Consequently, NK4 suppresses the interaction between HGF and c-Met, interrupts the HGF/c-Met signaling pathway, and thereby inhibits HGF-induced invasion and metastasis of tumor cells\(^9\,^10\).
In this study we used the replication-defective recombinant adenovirus rvAdCMV/NK4 expressing NK4 gene[11] to investigate the anti-tumor effects of NK4 in LS174T human colonic adenocarcinoma cells. The objective of this study was to explore whether NK4 may be used as a human colonic tumor treatment- a possibility that would require an experimental basis for the clinical application of manipulations of the NK4 gene product.

**MATERIALS AND METHODS**

**Virus and cell culture**

The construction and identification of the recombinant adenovirus rvAdCMV/NK4 with E1-E3 deletions have been described previously[11]. The recombinant adenovirus expressing β-galactosidase (Ad-LacZ) was generated in our laboratory using the same vector (data not published). These two viruses were replicated in a HEK293 human embryonic kidney cell line (American Type Culture Collection, Manassas, VA), which was maintained in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 100 mL/L fetal bovine serum (FBS) (Invitrogen). Culture titers were $8.9 \times 10^{12}$ infection focus units (ifu)/L and $6.4 \times 10^{12}$ ifu/L, respectively. LS174T human colonic adenocarcinoma and MRC-5 human fetal lung fibroblast cell lines were purchased from the Shanghai Institute of Cell Biology at the Chinese Academy of Sciences and cultured in RPMI 1640 medium (Invitrogen and treated with recombinant human HGF (PeproTech EC, Rocky Hill, NJ) at a final concentration of 10 μg/L for 48 h. The cell colony scattering was observed and photographed.

**Western blots**

Total cellular proteins were extracted and aliquots were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The blots were incubated with rabbit anti-human c-Met polyclonal antibody [1:250] (Zymed Laboratories, San Francisco, CA) or goat anti-human HGF-α polyclonal antibody [1:500] (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h at room temperature, followed by the addition of alkaline phosphatase (AP) conjugated secondary antibodies [1:5000] (Pierce, USA). AP was reacted with BCIP/NBT to visualize the bands.

**Adenovirus transduction efficiency analysis**

LS174T cells were seeded in 24-well plates until they reached 80% confluency, at which time they were infected with 1, 10, 25, 50 or 100 multiplicity of infection (MOI) with Ad-LacZ for 48 h. The cells were washed with phosphate buffered saline (PBS) and fixed in 100 mL/L formaldehyde for 10 min. Fixed cells were then stained with X-gal overnight at 37°C. The number of positive cells in each well was counted by viewing under a light microscope. Transduction = (the number of positive cells/number of total cells) × 100%.

**Cell proliferation assay**

Two thousand five hundred LS174T cells/well were seeded in 96-well plates in triplicate and divided into a control group, an Ad-LacZ group, and a rvAdCMV/NK4 group. The cells were cultured for 24 h (d 0), then mock infected or infected with viruses at 50 MOI for 1 h. The medium was then replaced with RPMI 1640 containing 100 mL/L FBS, and the cells were further cultured and harvested on d 0, 1, 3, and 5. Cell proliferation was analyzed using the CellTiter 96 AQueous One Solution Regent (Promega, Madison, WI) according to the manufacturer's protocol.

**Cell scatter assay**

LS174T (2.5 × 10^5 cells/well) was seeded in 12-well plates. After culturing for 4 to 7 d at 37°C, the medium was replaced with 20 mL/L FBS RPMI 1640 medium. The cell cultures were divided into a control group, an Ad-LacZ group (50 MOI), and a rvAdCMV/NK4 group (50 MOI) and treated with recombinant human HGF (PeproTech EC, Rocky Hill, NJ) at a final concentration of 10 μg/L for 48 h. The cell colony scattering was observed and photographed.

**In vitro scratch wound healing assay**

Cell migration was measured by an *in vitro* scratch wound healing assay as described elsewhere[12]. Briefly, after LS174T cells were infected by 50 MOI of rvAdCMV/NK4 or Ad-LacZ for 48 h, the cells were trypsinized and adjusted to a density of $2 \times 10^5$ cells/L, then seeded in 12-well plates. Monolayer cells were scratched with a sterile pipette tip, and , the cell migration was evaluated by counting the number of cells that had migrated from the wound edge after culturing for 24 h in 20 mL/L FBS-supplemented RPMI 1640 medium.

**Invasion Assay**

Invasion assay was carried out as previously described[13]. Matrigel, an artificial matrix gel extracted from mice EHS sarcoma (purchased from the Department of Cellular Biology, Center for Health Sciences, Peking University, Beijing, China), was diluted with DMEM medium to 1 g/L. Polycarbonate membranes of the upper wells in a Transwell chamber (Corning Costar No. 3422) were loaded with 50 mL of Matrigel gel and exposed to UV for 30 min. Serum free medium was added to the chamber for polymerizing at 37°C for 30 min before using. LS174T cells that had been transduced with rvAdCMV/NK4 or Ad-LacZ at an MOI of 50 for 72 h were adjusted to a density of $1.5 \times 10^6$ cells/L. Cell suspension (100 μL) was seeded on the upper wells and 600 μL of serum-free RPMI 1640 media, with or without 10 μg/L HGF, was added to the lower wells of the Transwell chamber. After cultivating for 72 h, the cells that degraded from the Matrigel and migrated through the 8 μm pores of the membrane at the bottom of the upper wells to the opposite side of the membrane were stained with Hematoxylin and Eosin and counted. Five microscopic fields ($\times 200$) were randomly selected for cell counting. The inhibitory rate = [(the number of invading cells in control group-the number in treated group)/the number of invading cells in control group] × 100%.

An inhibitory rate of more than 30%, $P < 0.05$, when compared with the group in which tumor cells in the upper wells and lower wells contained HGF, was considered to be evidence of an anti-invasion effect.
Statistical analysis

All data are expressed as means ± SD. Statistical comparisons were made using the Student's *t*-test. *P* < 0.05 was considered significant.

RESULTS

Expression of c-Met in the LS174T cell line

In this study we first examined the expression of c-Met, in order to test the reliability of using the colon cancer cell line LS174T as a study model. Western blot results showed that two specific bands were detectable in both LS174T and MRC-5 (Control): One was the 145 kD β-subunit of c-Met protein and the other was the 170 kD c-Met protein existing in the heterogeneous dimer form. This finding suggests that LS174T cells could be used as target cells of HGF and thus employed in further experimental studies. Expression of HGF was detected in MRC-5 cells, but was not detected in LS174T cells (Figure 1).

Adenovirus transduction optimization and NK4 gene expression

In order to optimize the gene transduction mediated by the adenovirus, we used the recombinant adenovirus Ad-LacZ, containing the report gene β-galactosidase, to infect LS174T cells at different MOI. We found that the infection rate increased with increasing MOI in a dose-dependent manner (data not shown). When the infection intensity reached 50 MOI, Ad-LacZ achieved a LS174T cell infection rate of more than 90% without pathological changes. Since overdose recombinant adenovirus infection will hurt cells and disturb cell growth, the optimal infection dose in all of our experiments was set as 50 MOI. rvAdCMV/NK4 infection of LS174T cells was confirmed by Western blot analysis. A specific NK4 protein band at 50 kD was detected, demonstrating that efficient expression of the NK4 gene mediated by the adenovirus was achieved in the LS174T cells (Figure 2). Thus, rvAdCMV/NK4-infected LS174T cells were found to be suitable for our experiments.

rvAdCMV/NK4 suppression of LS174T cell proliferation

We measured the effect of rvAdCMV/NK4 transduction on proliferation of LS174T cells. The proliferation rate of the tumor cells infected by rvAdCMV/NK4 was similar to that of the control group and the Ad-LacZ group (*P* > 0.05). As summarized in Figure 3, these data suggest that expression of the NK4 gene mediated by the adenovirus had no suppressive effect on LS174T cell proliferation.

Inhibition of LS174T cell scattering by rvAdCMV/NK4

Since HGF facilitates cell colony scatter, we designed this experiment to determine whether NK4 has an inhibitory effect on cell scattering. The results showed that intercellular adhesion among untreated LS174T cell colonies grown for 4 to 7 d was strong and that cells were not prone to scatter. But after HGF treatment, adhesion was relatively weak and the cells scattered in a spider-like pattern. In contrast, this HGF-effect was inhibited in rvAdCMV/NK4-infected cells. However, sole Ad-LacZ or rvAdCMV/NK4 infection did not influence intercellular adhesion, indicating that NK4 could specifically antagonize HGF-induced cell scattering (Figure 4).

Inhibition of LS174T cell movement by rvAdCMV/NK4

We performed a scratch wound healing assay to determine whether NK4 expressing recombinant adenovirus could attenuate HGF-induced cell motility. Without HGF treatment, the number of Ad-LacZ or rvAdCMV/NK4 infected LS174T cells that migrated into the scratch wound area were similar with that of uninfected LS174T cells. However with HGF treatment, we observed that less NK4-expressing cells migrated to the scratch wound area than control cells did, indicating that HGF activity of promoting tumor cell movement was antagonized by NK4. The number of cells migrating into the scratch wound areas of each group after HGF treatment was: 28.8 ± 7.1/mm².
in the control group; 29.3 ± 9.4/mm² in the Ad-LacZ group (P > 0.05 vs control group); and 10.2 ± 3.6/mm² in the rvAdCMV/NK4 group (P < 0.05 vs control group, Figure 5). These results suggest that the recombinant NK4 expressing adenovirus selectively antagonized HGF-induced cell movement.

**Inhibition of LS174T cell Invasion by rvAdCMV/NK4**

Tumor cell invasion of the basement membrane is a key process during metastasis. Matrigel, which is a kind of artificial matrix gel extracted from mouse EHS sarcoma, forms a membrane structure similar to the natural basement membrane structure in serum-free medium. The malignant invasion capacity of cells is revealed by their ability to penetrate into the filter membrane under the influence of an inductive chemo-attractant. The influence of specific factors on tumor cell invasive capacity can be observed in vitro by counting the number of cells that penetrate the filter membrane. The ability of untreated LS174T cells to degrade and penetrate the basement membrane was poor, but was improved when HGF was present in the lower chamber. The number of Ad-LacZ or rvAdCMV/NK4 infected LS174T cells that penetrated through the membrane without HGF in the lower chamber was similar to that of non-infected LS174T cells (P > 0.05). However, the invasive capacity of LS174T cells decreased significantly when HGF was present in the lower chamber (inhibitory rate 71.6%) after infection with rvAdCMV/NK4; meanwhile the inhibitory rate was only 7.3% in the Ad-LacZ treated group. This difference (P < 0.05) suggests that NK4 can specifically inhibit HGF-induced LS174T cell invasion (Figure 6).

**DISCUSSION**

Despite considerable advances in anesthesiology and surgical techniques as well as the development of new radiotherapy and chemotherapy strategies, the survival rate associated with colonic cancer has not been greatly improved. Tumor metastasis, including local metastasis to peripheral viscera and distant metastasis, is thought to be an important factor in determining survivability. It is reported that 15% to 35% of patients suffering from primary colonic cancer had liver metastasis when their primary tumors were diagnosed. Even among those patients who accept radical treatment for colonic cancer, 25% will have liver metastasis[14]. Accordingly, the prognosis of patients suffering from colonic cancer is primarily associated with the occurrence of metastasis, especially to the liver. Thus inhibition of metastasis will markedly improve the prognosis of colon cancer patients.

Changes in oncogenes and anti-oncogenes within cells contribute to tumorigenesis, but tumor metastasis behavior is primarily regulated by extracellular activated growth factors. Stromal cells can regulate tumor cell motility by releasing various cytokines, and consequently may initiate tumor metastasis[15-17]. HGF is one such important factor, released primarily by stroma fibroblasts, and initially identified and cloned as a potential liver cell mitogen[18,19]. HGF has also been found to facilitate cell movement and extracellular matrix breakthrough, resulting in the scatter of many kinds of tumor cells[4,20-22] and stimulating tumor cell prolifera-
tion and stroma cell angiogenesis\cite{23}. All of the effects of HGF are realized through its binding with the c-Met receptor, and c-Met receptors are over-expressed in many kinds of tumor cells\cite{24,26}. In this study we used the recombinant NK4 expressing adenovirus to infect the LS174T human colonic cancer cell line. Our results showed that NK4 could efficiently antagonize the effects of HGF, that is, it could inhibit the migration, scatter, and invasion of tumor cells. This suggests that NK4 is capable of blocking the HGF/c-Met signaling pathway and thereby may play an important role in antagonizing the invasion and metastasis of colonic cancer.

Highly malignant LS174T cells were harvested from poorly differentiated epithelial adenocarcinoma tissue. Western blot analysis indicated that c-Met protein was expressed in the LS174T cells. These findings demonstrate the feasibility of using recombinant adenovirus expressing NK4 to block the HGF/c-Met signaling pathway as a clinical intervention for colonic cancer. We did not detect HGF expression in the LS174T cells; however, the c-Met receptor was triggered clearly after HGF treatment, producing enhanced scatter, motility and invasion. These findings indicate that the HGF treatment was sufficient for this study. In in vitro cell proliferation experiments, rvAdCMV/NK4 had no effect on tumor cell proliferation. This is consistent with the studies of Kubota et al\cite{27} and Saimura et al\cite{28} indicating that the virus itself does not influence scatter and invasion.

A close relationship between the ability of tumor cells to move and their invasion capacity has been demonstrated\cite{29}. Thus suppression of tumor cell movement would be expected to inhibit invasion and metastasis\cite{30}. Initially, tumor cell movement appears as a scattering of the cells away from one another. We used a scatter assay and a scratch wound healing assay to reveal the inhibitory effects of NK4 on HGF. HGF reduced the intercellular homogeneous adhesion of LS174T cells; such as LS174T cells scattered and migrated. These effects were inhibited by rvAdCMV/NK4; however rvAdCMV/NK4 alone (without the presence of HGF) did not have any biological effects on LS174T cells, indicating that the effects of NK4 were specific for the HGF signal. The findings of Parr et al\cite{31} was shown that the growth factor TGF-β was able to facilitate tumor cell scattering in the presence of the NK4 protein and provide further evidence for the conclusion that NK4 specifically suppresses the influence of HGF.

Once tumor cells fall off the original tumors they invade the extracellular matrix of the host, and then penetrate the lymphatic system or the blood vessels, resulting in distant metastasis. The Matrigel material is similar to the extracellular matrix and therefore can be used to simulate tumor cell penetration into the cellular matrix around blood vessels. LS174T cells were able to degrade the Matrigel and migrate across the 8 μm membrane pores under the inductive influence of the chemo-attractant HGF. rvAdCMV/NK4 weakened the HGF-induced cell capacity for penetrating the basement membrane, but rvAdCMV/NK4 alone did not produce this effect. Dormancy therapy aimed at preventing angiogenesis has become a hot topic of discussion regarding with anti-tumor treatment\cite{32}. We did not investigate the antagonizing effect of NK4 on HGF-induced angiogenesis, which plays an important role in tumorigenesis and distant metastasis. However, recent studies have shown that the anti-angiogenesis effects produced by NK4 appear to be the result of not only a blockade of HGF-mediated effects, but also a blockade of effects mediated by vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)\cite{33,34}. Thus NK4 may be considered as a multi-potential anti-tumor therapeutic protein. Because NK4 has the potential to impact many aspects of tumorigenesis, it will be great applicable in the future clinical treatment of tumors.

In conclusion, this study demonstrated that adenoviral-mediated NK4 inhibits the invasion and metastasis of LS174T colonic cancer cells by blocking the HGF/c-Met signaling pathway in vitro. These findings establish an experimental basis for further studies in vivo.

**REFERENCES**

1. **Matsumoto K**, Nakamura T. HGF-c-Met receptor pathway in tumor invasion-metastasis and potential cancer treatment with NK4. In: Jiang WG, Matsumoto K, Nakamura T, ed. Growth factors and their receptors in cancer metastasis. Dordrecht: Kluwer Academic Publisher, 2001: 241-276
2. **Jiang W**, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. *Crit Rev Oncol Hematol* 1999; 29: 209-248
3. **Stuart KA**, Riordan SM, Lidder S, Costella L, Williams R, Skouteris GG. Hepatocyte growth factor/scatter factor-induced intracellular signalling. *Int J Exp Pathol* 2000; 81: 17-30
4. **Stella MC**, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. *Int J Biochem Cell Biol* 1999; 31: 1357-1362
5. **van der Voort R**, Taher TE, Derksen PW, Spaargaren M, van der Neut R, Pals ST. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. *Adv Cancer Res* 2000; 79: 39-90
6. **Jeffers M**, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. *J Mol Med (Berl)* 1996; 74: 505-513
7. **Longati P**, Comoglio PM, Bardelli A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. *Curr Drug Targets* 2001; 2: 41-55
8. **Date K**, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotropic actions of hepatocyte growth factor. *FEBS Lett* 1997; 420: 1-6
9. **Haddad R**, Lipson KE, Webb CP. Hepatocyte growth factor
expression in human cancer and therapy with specific inhibitors. *Anticancer Res* 2001; 21: 4243-4252

10 Matsumoto K, Nakamura T. Mechanisms and significance of bifunctional NK4 in cancer treatment. *Biochem Biophys Res Commun* 2005; 333: 316-327

11 Jie JZ, Wang JW, Wang W, Jiang XL, Wei Q, Hung T. Expression and characterization of HGF mutant NK4 in adenovirus vector. *Zhonggu Shiyian Zhenduanxue* 2003; 7: 397-400

12 Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. *Science* 1998; 280: 1614-1617

13 Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McKewan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. *Cancer Res* 1987; 47: 3239-3245

14 Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. *J Surg Oncol* 1998; 67: 194-202

15 Birchmeier C, Birchmeier W. Molecular aspects of mesenchymal-epithelial interactions. *Annu Rev Cell Biol* 1993; 9: 511-540

16 Sakakura T. New aspects of stroma-parenchyma relations in mammary gland differentiation. *Int Rev Cytol* 1991; 125: 165-202

17 Hu M, Pollock RE, Nakamura T, Nicholson GL. Human peritumoral and lung fibroblasts produce paracrine motility factors for recently established human sarcoma cell strains. *Int J Cancer* 1995; 62: 585-592

18 Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatocelomized rats. *Biochem Biophys Res Commun* 1984; 122: 1450-1459

19 Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. *Nature* 1989; 342: 440-443

20 Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoesis to hematopoesis. *J Cell Biol* 1995; 129: 1177-1180

21 Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J. Met-HGF/SF: tumorigenesis, invasion and metastasis. *Ciba Found Symp* 1997; 212: 119-130; discussion 130-132, 148-154

22 Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. *Cancer Sci* 2003; 94: 321-327

23 Maemondo M, Narumi K, Saijo Y, Usui K, Tahara M, Tazawa R, Hagiwara K, Matsumoto K, Nakamura T, Nukiwa T. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. *Mol Ther* 2002; 5: 177-185

24 Di Renzo MF, Narsimhan RP, Olivero M, Brett S, Giordano S, Medico E, Gagli P, Zara P, Comoglio PM. Expression of the Met/HGF receptor in normal and neoplastic human tissues. *Cancer Gene Ther* 1996; 3: 47-52

25 Kaji M, Yonemura Y, Harada S, Liu X, Terada I, Yamamoto H. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. *Cancer Gene Ther* 1996; 3: 393-404

26 Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. *Br J Cancer* 2001; 84: 864-873

27 Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshihira M, Matsumoto K, Nakamura T, Yamagishi H. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. *Cancer Sci* 2004; 95: 321-327

28 Saimura M, Nagai E, Mizumoto K, Maehara N, Okino K, Katano M, Matsumoto K, Nakamura T, Narumi K, Nukiwa T, Tanaka M. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. *Cancer Gene Ther* 2002; 9: 799-806

29 Grimstad IA. Direct evidence that cancer cell locomotion contributes importantly to invasion. *Exp Cell Res* 1987; 173: 515-523

30 Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. *Cancer Res* 1995; 55: 1856-1862

31 Parr C, Hiscox S, Nakamura T, Matsumoto K, Jiang WG. NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. *Int J Cancer* 2000; 85: 563-570

32 Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK. Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. *Cancer Res* 2000; 60: 1442-1448

33 Ueda K, Iwahashi M, Matsuura I, Nakamori M, Nakamura M, Ojima T, Naka T, Ishida K, Matsumoto K, Nakamura T, Yamaue H. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. *Eur J Cancer* 2004; 40: 2135-2142

34 Nakabayashi M, Morishita R, Nakagami H, Kuha K, Matsumoto K, Nakamura T, Tano Y, Kaneda Y. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. *Diabetologia* 2003; 46: 115-123